COVID-19 Archives | BioTuesdays

Developments

U of Maryland School of Medicine lab approved as development site for RNA Disease Diagnostics COVID-19 test

The FDA registered the laboratory of Dipanjan Pan, Ph.D., at the University of Maryland School of Medicine, as an approved laboratory development site for RNA Disease Diagnostics’ (RNADD) Antisense COVID-19 molecular...

June 3, 2021

Developments

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

iBio (NYSE American:IBIO) updated its IBIO-201 program and reported progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201...

May 7, 2021

Developments

RNA Disease Diagnostics stepwise protocol for molecular diagnosis of COVID-19 published in Nature Protocols

RNA Disease Diagnostics’ stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for COVID-19 was published in Nature Protocols. The test uses a unique dual-pronged molecular sensing approach that...

May 6, 2021

Markets

Maxim starts MediciNova at buy; PT $15

Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...

March 10, 2021

Developments

Soricimed approach to COVID-19 being validated by other researchers

Researchers at Rush University Medical Center in Chicago are developing a new peptide treatment to prevent COVID-19 symptoms that supports the approach being taken by closely-held Soricimed Biopharma. The peptide...

January 25, 2021

Developments

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

aTyr Pharma (NASDAQ:LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do...

January 5, 2021

Developments

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...

December 22, 2020

Developments

Soricimed to investigate SOR-C13 to treat COVID-19

Closely-held Soricimed Biopharma, benefiting from funding support from the National Research Council of Canada Industrial Research Assistance Program, will investigate the potential therapeutic role its cancer drug...

December 17, 2020

Developments

Capricor initiates dosing in Phase 2 COVID-19 trial

Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19. CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy...

November 24, 2020

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Tag - COVID-19

U of Maryland School of Medicine lab approved as development site for RNA Disease Diagnostics COVID-19 test

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

RNA Disease Diagnostics stepwise protocol for molecular diagnosis of COVID-19 published in Nature Protocols

Maxim starts MediciNova at buy; PT $15

Soricimed approach to COVID-19 being validated by other researchers

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

Soricimed to investigate SOR-C13 to treat COVID-19

Capricor initiates dosing in Phase 2 COVID-19 trial

Humanigen reports positive interim data from Phase 3 COVID-19 trial

General

More